WallStSmart

Stevanato Group SpA (STVN)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 159% more annual revenue ($3.07B vs $1.19B). WST leads profitability with a 16.1% profit margin vs 11.8%. WST appears more attractively valued with a PEG of 2.89. WST earns a higher WallStSmart Score of 55/100 (C-).

STVN

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 6.5Value: 4.7Quality: 6.3
Piotroski: 4/9Altman Z: 2.39

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

STVNSignificantly Overvalued (-262.8%)

Margin of Safety

-262.8%

Fair Value

$4.30

Current Price

$14.18

$9.88 premium

UndervaluedFair: $4.30Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

STVN2 strengths · Avg: 8.0/10
Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.9%8/10

Strong operational efficiency at 20.9%

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

STVN3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

EPS GrowthGrowth
0.3%4/10

0.3% earnings growth

PEG RatioValuation
3.572/10

Expensive relative to growth rate

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : STVN

The strongest argument for STVN centers on Price/Book, Operating Margin.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : STVN

The primary concerns for STVN are Revenue Growth, EPS Growth, PEG Ratio.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

STVN profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

WST scores higher overall (55/100 vs 51/100), backed by strong 16.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Stevanato Group SpA

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in integrated solutions tailored for the pharmaceutical and biotechnology sectors. The company excels in the design and manufacturing of glass and polymer packaging for injectable medications, improving efficiency and reliability in the drug delivery process. With a strong commitment to quality and sustainability, Stevanato is well-positioned to benefit from the growing biopharmaceutical market, making it an attractive prospect for institutional investors looking to invest in healthcare innovation and technology advancement.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?